Home | News

27/07/2016 - Briefing Paper: Brexit and the Pharmaceutical Industry

In this briefing paper Andrew Lilico, Executive Director, and Kareen El Beyrouty, Senior Consultant at Europe Economics, discuss the key implications of Brexit for the pharmaceutical industry. The discussion focuses on national drug budgets, parallel trade and intellectual property, trade agreements, R&D funding and the free movement of people, access to finance, and regulatory governance. These issues are discussed through the lens of what we view as the most likely outcomes of Brexit and we highlight some of the key questions that the pharmaceutical industry should be thinking through at this time. 

To purchase the briefing paper, please email enquiries@europe-economics.com.